Modification of exhaled air nitric oxide in patients with asthma - cortisone monotherapy or dual inhalation therapy?
| Autor: | Rodica Ungur, Nicoleta Stefania Motoc, Teodora Alexescu, Doina Adina Todea, Carmen Monica Pop, Victoria Maria Ruta, Adina Man Milena, Razvan Codea, Stefania Cozac, Sorina Cezara Coste, Dan Valean |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Adult
Male medicine.medical_specialty Respiratory Therapy inhalation monotherapy Nitric Oxide Nitric oxide chemistry.chemical_compound Young Adult Internal medicine Administration Inhalation medicine Humans GE1-350 In patient Dual therapy Waste Management and Disposal Ecology Evolution Behavior and Systematics Asthma Inhalation wheezing business.industry fractional expired nitric oxide (feno) Public Health Environmental and Occupational Health Agriculture dual therapy Guideline respiratory system medicine.disease Combined Modality Therapy respiratory tract diseases Environmental sciences Cortisone chemistry Observational study Female business medicine.drug |
| Zdroj: | Annals of Agricultural and Environmental Medicine, Vol 28, Iss 1, Pp 89-93 (2021) |
| ISSN: | 1898-2263 |
| Popis: | Introduction Asthma, a chronic lung disease, is a major health challenge worldwide with increased addressability to health services. There are different asthma phenotypes, which have different evolution and can be specifically tracked. The measurement of fractional expired nitric oxide (FeNo) with different devices reflects the eosinophilic inflammation of the airways, and can be used to evaluate the allergic phenotype and predict the treatment responses. The new GINA (Global Initiative for Asthma) guideline recommends FeNO monitoring to assess adherence to cortisone treatment in high doses before prescribing biological treatment, and as a means of monitoring the decrease in oral corticosteroid treatment. Objective The aim of the study is to analyze the applicability of FeNO in monitoring response to therapy. Material and methods An observational study was carried out on 129 subjects with a previously established diagnosis of asthma. The research was based on the determination of FeNO with NObreath. Those with intermediate FeNO received a low dose of inhaled corticosteroids in mono/dual therapy, those with increased FeNO received medium ICS mono/dual therapy. FeNO testing, its values and doses of ICS were below the the ATS / ERS guidelines. Results FeNO reduction is strictly dependent on the cortisone dose. Applying the dual therapy from the beginning does not bring additional benefits in comparison with cortisone in monotherapy, in terms of FeNO value. Conclusions Recommendations that include FeNO testing can help monitor response to treatment. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|